Amivantamab with lazertinib is in clinical development for the treatment of patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). NSCLC makes up the majority of lung cancers in the UK. In locally advanced NSCLC, the cancer has spread into tissues around the lungs, and metastatic NSCLC is when the cancer starts in the lungs and then spreads to other areas of the body. Epidermal growth factor receptor (EGFR) is a protein that is involved in processes that control cell division and survival. Changes (mutations) in EGFR causes cancer cells to divide more rapidly. More than 60% of NSCLCs express EGFR, making it an important therapeutic target for the treatment of these tumours.
Amivantamab with lazertinib for previously untreated locally advanced or metastatic non-small-cell lung cancer
Amivantamab with lazertinib is in clinical development for the treatment of patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). NSCLC makes up the majority of lung cancers in the UK.
Indications:
Non-small-cell lung cancer (NSCLC)
Therapeutic Areas:
Lung and Respiratory Cancer
Year:
2023